Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy

JAMA

Volumn 298, Issue 4, 2007, Pages 405-412

  Maron, Barry J ^a   Spirito, Paolo ^b   Shen, Win Kuang ^c   Haas, Tammy S ^a   Formisano, Francesco ^b   Link, Mark S ^d   Epstein, Andrew E ^e   Almquist, Adrian K ^a   Daubert, James P ^f   Lawrenz, Thorsten ^g   Boriani, Giuseppe ^h   Estes III, N A Mark ^d   Favale, Stefano ⁱ   Piccininno, Marco ^b   Winters, Stephen L ^j   Santini, Massimo ^k   Betocchi, Sandro ^l   Arribas, Fernando ^m   Sherrid, Mark V ⁿ   Buja, Gianfranco ^o   Semsarian, Christopher ^p   Bruzzi, Paolo ^q   more..

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^b GALLIERA HOSPITAL   (Italy)

^c MAYO CLINIC   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^g UNIVERSITY OF MÜNSTER   (Germany)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ UNIVERSITY OF BARI   (Italy)

^j MORRISTOWN MEMORIAL HOSPITAL   (United States)

^k SAN FILIPPO NERI HOSPITAL   (Italy)

^l UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^m HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁿ ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^o UNIVERSITY OF PADOVA   (Italy)

^p ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^q UNIVERSITY OF GENOA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; AUSTRALIA; CAUSE OF DEATH; COHORT ANALYSIS; DEFIBRILLATOR; EUROPE; FAMILY HISTORY; FEMALE; FOLLOW UP; HEART ARREST; HEART ARRHYTHMIA; HEART DEATH; HEART LEFT VENTRICLE HYPERTROPHY; HEART RHYTHM; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HOLTER MONITORING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTATION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SHOCK; SYMPTOMATOLOGY; SYNCOPE; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED STATES; AGED; MIDDLE AGED; REGISTER; SUDDEN DEATH;

ADULT; AGED; CARDIOMYOPATHY, HYPERTROPHIC; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HUMANS; MALE; MIDDLE AGED; REGISTRIES; RISK ASSESSMENT; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

EID: 34547188258     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.298.4.405     Document Type: Article

References (35)

1. Teare D. Asymmetrical hypertrophy of the heart in young athletes. Br Heart J. 1958;20(1):1-8.
2. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42(9):1687-1713.
3. Braunwald E, Lambrew C, Rockoff D, et al. Idiopathic hypertrophic subaortic stenosis, I: a description of the disease based upon an analysis of 64 patients. Circulation. 1964;30(suppl IV):1-217.
4. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287(10):1308-1320.
5. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med. 1997;336(11):775-785.
6. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy predicts the risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342(24):1778-1785.
7. Maron BJ. Sudden death in young athletes. N Engl J Med. 2003;349(11):1064-1075.
8. Maron BJ, Shen W-K, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000;342(6):365-373.
9. Jayatilleke I, Doolan A, Ingles J, et al. Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. Am J Cardiol. 2004;93(9):1192-1194.
10. Woo A, Monakier D, Harris L, et al. Determinants of implantable defibrillator discharges in high risk patients with hypertrophic cardiomyopathy. Heart. In press.
11. Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337(22):1576-1583.
12. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877-883.
13. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225-237.
14. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21):2151-2158.
15. Almquist AK, Montgomery JV, Haas TS, Maron BJ. Cardioverter-defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy. Heart Rhythm. 2005;2(8):814-819.
16. Boriani G, Maron BJ, Shen W-K, Spirito P. Prevention of sudden death in hypertrophic cardiomyopathy: but which defibrillator for which patient? Circulation. 2004;110(15):e438-e442.
17. Maron BJ, Estes NAM III, Maron MS, Almquist AK, Link MS, Udelson J. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation. 2003;107(23):2872-2875.
18. Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348(4):295-303.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
20. Seggewiss H. Percutaneous transluminal septal myocardial ablation: a new treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J. 2000;21(9):704-707.
21. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995;346(8969):211-214.
22. Valeti US, Nishimura RA, Holmes DR, et al. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2007;49(3):350-357.
23. Hauser RG, Maron BJ. Lessons from the failure and recall of an implantable cardioverter defibrillator. Circulation. 2005;112(13):2040- 2042.
24. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA. 1999;281(7):650-655.
25. Spirito P, Chiarella F, Carratino L, Berisso MZ, Bellotti P, Vecchi C. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med. 1989;320(12):749-755.
26. Goldenberg I, Moss AJ, Maron BJ, Dick AW, Zareba W. Cost effectiveness of implanted defibrillators in young people with inherited cardiac arrhythmias. Ann Noninvasive Electrocardiol. 2005;10(4)(suppl 4):67-83.
27. Primo J, Geelen P, Brugada J, et al. Hypertrophic cardiomyopathy: role of the implantable cardioverter-defibrillator. J Am Coll Cardiol. 1998;31(5):1081-1085.
28. Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices. Circulation. 2002;106(16):2145-2161.
29. Marín F, Gimeno JR, Payá E, et al. The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy: experience at three centers. Rev Esp Cardiol. 2006;59(6):537-544.
30. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet. 2004;363(9424):1881-1891.
31. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation. 2000;102(8):858-864.
32. Corrado D, Leoni L, Link MS, et al. Implantable cardioverter- defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation. 2003;108(25):3084-3091.
33. Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006;114(3):216-225.
34. Maron BJ, Olivotto I, Bellone P, et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;39(2):301-307.
35. Steinbrook R. The controversy over Guidant's implantable defibrillators. N Engl J Med. 2005;353(3):221-224.